The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results

Journal of the Neurological Sciences

Volumn 322, Issue 1-2, 2012, Pages 96-101

  Amenta, Francesco ^a   Carotenuto, Anna ^a   Fasanaro, Angiola Maria ^b   Rea, Raffaele ^a   Traini, Enea ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Association; Cerebrovascular injury; Choline alphoscerate; Donepezil

Indexed keywords

CHOLINE ALFOSCERATE; DONEPEZIL; PLACEBO;

ADULT; AGE RELATED WHITE MATTER CHANGES; AGED; ALZHEIMER DISEASE; ALZHEIMER'S DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; ASTHENIA; BASIC ACTIVITIES OF DAILY LIVING; CEREBROVASCULAR ACCIDENT; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DSM-IV; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; INSTRUMENTAL ACTIVITIES OF DAILY LIVING; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 84867572774     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.07.003     Document Type: Article

References (21)

1. E. Giacobini Cholinergic foundations of Alzheimer's disease therapy J Physiol Paris 92 1998 283 287
2. F. Amenta, L. Parnetti, V. Gallai, and A. Wallin Treatment of cholinergic dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev 122 2001 2025 2040
3. S. Gauthier Advances in the pharmacotherapy of Alzheimer's disease CMAJ 166 2002 616 623
4. H.R. Brashear Galantamine in the treatment of vascular dementia Int Psychogeriatr 15 2003 187 193
5. G.C. Román Vascular dementia: distinguishing characteristics, treatment, and prevention J Am Geriatr Soc 51 2003 S296 S304
6. R.W. Jones Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 18 2003 S7 S13
7. J.P. Higgins, and L. Flicker Lecithin for dementia and cognitive impairment Cochrane Database Syst Rev 2003 CD001015
8. L. Parnetti, F. Mignini, D. Tomassoni, E. Traini, and F. Amenta Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for reevaluation? J Neurol Sci 257 2007 264 269
9. H. Kaduszkiewicz, T. Zimmermann, H.P. Beck-Bornholdt, and H. van den Bussche Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials BMJ 331 2005 321 327
10. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 1 2006 CD005593
11. J. Birks, and R. Harvey Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst Rev 1 2006 CD001190
12. F. Amenta, S.K. Tayebati, D. Vitali, and M.A. Di Tullio Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission Mech Ageing Dev 127 2006 173 179
13. S.K. Tayebati, M.A. Di Tullio, D. Tomassoni, and F. Amenta Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats J Neurol Sci 283 2009 187 194
14. M.F. Folstein, S.E. Folstein, and P.R. Mc Hugh Mini Mental State: a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
15. L.O. Wahlund, F. Barkhof, and F. Fazekas A New Rating Scale for Age Related White Matter Changes applicable to MRI and CT Stroke 32 2001 1318 1322
16. P.T. Francis, M.J. Ramírez, and M.K. Lai Neurochemical basis for symptomatic treatment of Alzheimer's disease Neuropharmacology 59 2010 221 229
17. H. Kavirajan, and L.S. Schneider Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials Lancet Neurol 6 2007 782 792
18. B.J. Everitt, and T.W. Robbins Central cholinergic systems and cognition Annu Rev Psychol 48 1997 649 684
19. D.S. Auld, T.J. Kornecook, S. Bastianetto, and R. Quirion Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies Prog Neurobiol 68 2002 209 245
20. R. Schliebs, and T. Arendt The significance of the cholinergic system in the brain during aging and in Alzheimer's disease J Neural Transm 113 2006 1625 1644
21. L. Parnetti, F. Amenta, and V. Gallai Choline alphoscerate in cognitive decline and in acute cerebrovascular disease. An analysis of published clinical data Mech Ageing Dev 122 2001 2041 2055